accountIn the address he offered details on how biotechnology companies have supplemented venture capital with venture debt and big pharma venture funds as attractive long-term capital sources. To conclude his presentation, Mr. Gaito outlined the keys to a...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Leading Venture Capital, Biotech and Financial Experts Weigh-in on the Future of Biotechnology
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account